Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Clindamycin

Clindamycin

Lincosamide (PO, IV)

AnaerobesCA-MRSAC diff

Indication

MRSA SSTI β€’ odontogenic β€’ aspiration pneumonia anaerobes β€’ toxic shock adjunct β€’ PCP alt

At a glance

INDICATIONS (CORE USE)

Anaerobes + **CA-MRSA** SSTI oral/IV β€” **C. diff risk high**; **rapid IV** cardiovascular collapse rare β€” infuse slowly.

ADULT DOSE (STANDARD)

300–450 mg PO TID or 600 mg IV q6–8h severe

MAX DOSE

~4.8 g/day IV protocols rare β€” toxic

Route

PO, IV, topical

PEDIATRIC DOSE

30–40 mg/kg/day divided q6–8h (max per reference)

Do not miss

Must-not-miss safety points

Major warning

- **C. difficile colitis** β€” among highest-risk antibiotics - **Rapid IV bolus** β†’ hypotension / cardiac arrest β€” infuse per policy - Not empiric for polymicrobial intra-abd without beta-lactam backbone (Bacteroides resistance varies) - Neuromuscular blockade potentiation

Indications

USE IF: Suspected CA-MRSA SSTI oral option; anaerobic infection; toxic shock toxin suppression adjunct. AVOID IF: Mild cellulitis likely strep only; prolonged therapy without strong indication.

Primary

  • Skin/soft tissue infection when CA-MRSA suspected and oral therapy appropriate
  • Odontogenic / head-neck anaerobic infections (often with surgical drainage)

Secondary

  • Aspiration pneumonia / lung abscess anaerobic coverage component
  • Streptococcal toxic shock clindamycin protein synthesis suppression adjunct β€” ID-guided

Other

  • Pneumocystis jirovecii alternative regimens β€” specialist
  • Babesia (specialist)

Dosing

STANDARD (ADULT PO)

300–450 mg PO q6–8h OR 600–900 mg IV q8h severe

ADULT DOSE

600–900 mg IV q8h severe; 300–450 mg PO q6–8h

PEDIATRIC DOSE

Weight-based.

MAX DOSE

High-dose IV toxic β€” rare tox protocols only.

Practical Note

IV infusion 10–60 min per concentration policy.

Warnings

Clinical warnings

  • C. diff
  • Esophagitis with capsules β€” water

Adverse effects

  • diarrhea
  • rash
  • phlebitis

Contraindications

  • Hypersensitivity to clindamycin

Drug interactions

  • Neuromuscular blockers
  • erythromycin antagonism theoretical

Special populations

Pediatrics

30–40 mg/kg/day divided q6–8h (max per reference)

Pregnancy

Generally acceptable when indicated

Lactation

low milk levels relative risk low.

Renal impairment

No adjustment. **CrCl scaffold (FMBM β€” titrate to FDA/SFDA label + institutional pharmacy nomogram):** - **CrCl β‰₯50** β†’ no major CrCl adjustment - **CrCl 10–50** β†’ no major CrCl adjustment - **CrCl <10** β†’ minimal change; **severe hepatic** β†’ reduce/extend per label

Hepatic impairment

Severe hepatic impairment β€” reduce dose / extend interval.

Elderly

C. diff risk highest demographic.

Administration

Slow IV; PO with full glass water.

Monitoring

  • Monitor: - Diarrhea during or after therapy β†’ **test for C. difficile** - First IV doses β†’ **BP / HR** (rate-related reactions) - Diarrhea β†’ C. diff testing - BP during infusion first doses
  • Recheck: - No clinical improvement at 48–72h β†’ reassess diagnosis, resistance, source control, and drug interactions - If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)

Overdose / toxicity

Clinical Picture

**Life-threatening (first):** **cardiac arrest** / shock (rare rapid IV). **Secondary:** oral GI upset; **C. diff** (clinical course, not acute OD-specific).

Immediate Actions

Stop infusion β†’ ACLS if arrest; supportive

Antidote

No specific antidote; treat complications (e.g. anaphylaxis β†’ epinephrine per ACLS)

Decontamination

PO overdose β†’ supportive; charcoal if very recent

Escalation

Refractory shock β†’ **ICU**

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

**MRSA oral** + **anaerobes**. **C. diff on steroids** β€” shortest course possible. **Slow IV** β€” bolus kills mood and sometimes patients.

Clinical pearls

Stewardship: cephalexin may suffice simple cellulitis if no MRSA risk. Toxin suppression in toxic shock is adjunct only β€” source + beta-lactam backbone. Topical acne clinda drives resistance β€” dermatology nuance. *Stewardship (all antimicrobials):* Empiric choice β†’ syndrome severity + **local antibiogram**; shortest effective course.

Stewardship & safety

  • C. diff
  • Infusion rate
  • Stop if diarrhea

Pharmacokinetics

Good bone penetration; hepatic metabolism; penetrates abscess.

Mechanism of action

50S ribosome β€” inhibits protein synthesis; bacteriostatic.

Common brand names

Global data (no country-specific data available)

Saudi Arabia

(placeholder β€” verify local formulary)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • Empiric choice β†’ tie to syndrome, severity, and local antibiogram β€” not habit.
  • IV β†’ PO step-down when oral bioavailability and susceptibility allow.
  • Do not use antibiotics for uncomplicated viral illness β€” stewardship.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • Sanford Guide
  • IDSA / ESCMID (indication-specific)
  • Local antimicrobial stewardship / hospital formulary
  • FDA / SFDA / regional product labeling
  • Sanford Guide
  • IDSA / ESCMID (indication-specific)
  • Local antimicrobial stewardship / hospital formulary
  • FDA / SFDA / regional product labeling

Do not miss

  • Uncomplicated viral URI/bronchitis β†’ antibiotics rarely indicated
  • Narrow or stop when susceptibilities + clinical stability allow
  • Toxic megacolon / fulminant CDI after clinda course.
  • Using clinda monotherapy for severe intra-abd sepsis without GNR coverage.
  • C. diff
  • Infusion rate
  • Stop if diarrhea